Catheter Precision Inc(VTAK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.34 | Insider Own | 10.74% | Shs Outstand | 19.0M | Perf Week | -1.76% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 16.9M | Perf Month | -24.76% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 7.93% | Short Float | 1.35% | Perf Quarter | -80.29% |
| Income | -0.01B | P/S | 1.49 | EPS this Y | - | Inst Trans | 5.52% | Short Ratio | 0.03 | Perf Half Y | -83.76% |
| Sales | 0.00B | P/B | 0.03 | EPS next 5Y | - | ROA | -41.66% | Short Interest | 0.23M | Perf YTD | -91.75% |
| Book/sh | 4.87 | P/C | 1.55 | EPS past 3/5Y | 85.23% 84.88% | ROE | -106.82% | 52W High | -95.28% ($3.20) | Perf Year | -94.19% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | 288.2% 25.89% | ROIC | -57.05% | 52W Low | 17.24% ($0.13) | Perf 3Y | -99.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 90.58% | Gross Margin | -68.83% | Volatility(W/M) | 9.83% 8.46% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | 7.85 | Sales Y/Y TTM | 219.17% | Oper. Margin | -629.77% | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.18 | EPS Q/Q | 87.32% | Profit Margin | -711.49% | RSI (14) | 34.42 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.19 | Sales Q/Q | 380.66% | SMA20 | -5.9% ($0.16) | Beta | -1.09 | Target Price | $38 |
| Payout | - | Debt/Eq | 0.82 | Earnings | - | SMA50 | -28.76% ($0.21) | Rel Volume | 0.16 | Prev Close | $0.15 |
| Employees | 17 | LT Debt/Eq | 0.3 | EPS/Sales Surpr. | 8.64% -4% | SMA200 | -85.25% ($1.02) | Avg Volume(3M) | 8.11M | Price | $0.15 |
| IPO | 2018/9/27 | Option/Short | No/Yes | Trades | 958 | Volume | 1,305,549 | Change | -0.66% |
A medical device company specializing in the design, manufacture, and sale of equipment in the cardiac electrophysiology (EP) field. Its flagship products include the VIVO 3D cardiac mapping system and the LockeT suture retention device.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
VTAK has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $149. Peers typically go for $141.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.9%.
Tap to view numbers
It ranks #137 of 144 in the industry
Based on market cap of $3M.
AIDX#136 20/20 Biolabs Inc $3M PER - VTAK#137 Catheter Precision Inc $3M PER - 
ADGM#137 Adagio Medical Holdings Inc $3M PER - 
IVF#138 INVO Fertility Inc $3M PER - 
BJDX#139 Bluejay Diagnostics Inc $3M PER - 
FAQ
What kind of company is VTAK?
VTAK belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of VTAK?
The market cap of VTAK is approximately $3M, ranking 5,804 within its sector.
What is the 52-week high and low for VTAK?
VTAK has recorded a 52-week high of $3.20 and a low of $0.13.
